1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fertility Market in the US 2016-2020

Fertility Market in the US 2016-2020

  • January 2016
  • -
  • Infiniti Research Limited
  • -
  • 63 pages

About Fertility

Couples with fertility issues are unable to conceive even after regular unprotected coitus (six months if the woman is over age 35). Female or male infertility factors account for one-third of the cases, where a couple is unable to conceive. In the rest of the cases, the cause is either unknown or a combination of both male and female infertility factors.

In males, low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm can lead to infertility. In females, hormonal changes, fallopian tube damage, endometriosis, and cervical abnormalities can lead to infertility. Diagnosing the cause of infertility can be difficult but people with fertility issues have many treatment options depending on the underlying problem.

Technavio’s analysts forecast the fertility services market in the US to grow at a CAGR of 4.07% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the fertility treatment market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of fertility drugs and the use of assisted reproductive technology (ART).

The market is divided into the following segments based on treatment type:
- ART
- Infertility drugs

Technavio's report, Fertility Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- Cellcura
- CooperSurgical
- Intramed
- Ferring Pharmaceuticals
- Merck


Other prominent vendors
- Abbott Laboratories
- AbbVie
- Actavis
- Apricus Biosciences
- AstraZeneca
- Auxogyn
- Bristol-Myers Squibb
- Elelixis Diagnostics
- Eli Lilly
- EMD Serono
- IKS International
- In Vitro Care
- Invo Bioscience
- Irvine Scientific
- IVFtech Aps
- Life Global
- Medical Electronic Systems
- Meditex
- Novartis
- Ovascience
- Pantec Biosolutions
- Pfizer
- Sanofi
- Vivus
- Xytex Cryo International

Market driver
- Emergence of ART and acceptance of same-sex marriage
- For a full, detailed list, view our report

Market challenge
- High cost of fertility treatment
- For a full, detailed list, view our report

Market trend
- Increase in M&A
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Fertility Market in the US 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Regulatory scenario in the US
PART 06: Market landscape
- Market overview
- Five forces analysis
PART 07: Infertility: An overview
- Etiology
- Etiology: Female infertility
- Signs and symptoms
- Tests and diagnosis
- Treatment
PART 08: Stages of fertility treatment
PART 09: Cost analysis of ART
- Direct cost
- Indirect cost
PART 10: Market segmentation by type
- Infertility drugs
- Fertility drugs market in US
- ART
- ART market in US
PART 11: Market drivers
- Emergence of ART and acceptance of same-sex marriage
- Increasing success rate of infertility treatment
- Increase in infertility complications
PART 12: Impact of drivers
PART 13: Market challenges
- High cost of fertility treatment
- Complications of fertility services
- Limited reimbursement
- Minimal regulations
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Increase in MandA
- Rise in RandD
- Establishment of new fertility clinics
PART 16: Vendor landscape
- Competitive scenario
- Key news
- Mergers and acquisitions
- Licensing and collaborations
- Market share analysis
- Other prominent vendors
PART 17: Appendix
- List of abbreviations
PART 18: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Number of ART procedures in US 2002-2013
Exhibit 03: Number of ART procedures in the US by fresh embryo from non-donor oocytes
Exhibit 04: Number of ART procedures in the US by thawed embryos from non-donor oocytes
Exhibit 05: Fertility services market in US 2015-2020 ($ billions)
Exhibit 06: Five forces analysis
Exhibit 07: Types of infertility
Exhibit 08: Causes of male infertility
Exhibit 09: Causes of female infertility
Exhibit 10: Stages of fertility treatment
Exhibit 11: Segmentation of fertility services market in US by treatment type
Exhibit 12: Segmentation of fertility services market in US by treatment type 2015
Exhibit 13: Fertility drugs market in US 2015-2020 ($ billions)
Exhibit 14: Types of ART
Exhibit 15: IVF procedure
Exhibit 16: Success rate of IVF
Exhibit 17: Infertility rate in US by sex 2010
Exhibit 18: Infertility rate in US by age 2002 and 2010
Exhibit 19: Different categories of ART in US
Exhibit 20: Comparison of fresh and frozen ART cycle
Exhibit 21: ART market in US 2015-2020 ($ billions)
Exhibit 22: ART procedures and number of infants born in US 2002-2011 (thousands)
Exhibit 23: Same-sex married couples in US 2008-2013 (thousands)
Exhibit 24: Infertility by reproductive group in US
Exhibit 25: Adult Americans with obesity 2012
Exhibit 26: Adult Americans with obesity 2030
Exhibit 27: Impact of drivers
Exhibit 28: Average cost of fertility services in US
Exhibit 29: States that require people to have insurance coverage for fertility services
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Recent MandA
Exhibit 32: Number of fertility clinics in US 2010-2014
Exhibit 33: CellCura: Key takeaways
Exhibit 34: CooperSurgical: Business segmentation by revenue 2014
Exhibit 35: IntegraMed: Key takeaways
Exhibit 36: Ferring Pharmaceuticals: Key takeaways
Exhibit 37: Merck: Business segmentation by revenue 2014
Exhibit 38: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 39: Merck: Geographical segmentation by revenue 2014
Exhibit 40: Merck: Key drivers in fertility services sector
Exhibit 41: Merck: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • October 2016
  • by Grand View Research

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one ...

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by Global Data

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H2, 2016" provides an overview ...

Viral Protease Inhibitors -Pipeline Insights, 2017

Viral Protease Inhibitors -Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s, “Viral Protease Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Viral Protease Inhibitors. ...


Download Unlimited Documents from Trusted Public Sources

HIV AIDS Statistics and HIV Antiviral Market in China

  • February 2017
    11 pages
  • HIV AIDS  

    Infectious Dise...  

    HIV Antiviral  

  • China  

    United States  

View report >

HIV AIDS Statistics and HIV Antiviral Market in the US

  • January 2017
    4 pages
  • HIV AIDS  

    HIV Antiviral  

  • United States  

View report >

HIV Antiviral Market in Africa

  • January 2017
    27 pages
  • Antiviral  

    HIV Antiviral  

    HIV AIDS  

  • Africa  

    Asia  

View report >

Related Market Segments :

HIV Antiviral
Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.